This is a working overview of Immune modulation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
=== Catherine E. Costello Award for Exemplary Achievements in Proteomics (the former Catherine E. Costello Lifetime Achievement in Proteomics Award) (since 2019) === 2026 Lingjun Li 2025 Ileana Cristea 2024 Jennifer Van Eyk 2022 Catherine C. Fenselau 2019 Catherine E. Costello
The Institut International du Froid (IIF), French for the International Institute of Refrigeration (IIR), is an independent intergovernmental science and technology-based organisation that promotes knowledge of refrigeration and associated technologies and applications on a global scale that improve quality of life in a cost-effective and environmentally sustainable manner. Areas of focus include:
The Vietnam era saw the testing and shaping of Special Forces policy and action for the United States. The mission of the Special Forces changed rapidly in the first years from a force that had initially been used like its WWII predecessors as an internal strike force into a training force which helped develop unconventional warfare and counterinsurgency tactics. The period between 1961 and 1965 was especially formative. The first U.S. Special Forces operations in Vietnam were in 1957, when soldiers from the 1st Special Forces Group trained fifty-eight Vietnamese Army soldiers at the Commando Training Center in Nha Trang. Special Forces units deployed to Laos as "Mobile Training Teams" (MTTs) in 1961, Project White Star (later named Project 404), and they were among the first U.S. troops committed to the Vietnam War. Beginning in the early 1950s, Special Forces teams deployed from the United States and Okinawa to serve as advisers for the fledgling South Vietnamese Army. As the United States escalated its involvement in the war, the missions of the Special Forces expanded as well. Since Special Forces were trained to lead guerrillas, it seemed logical that they would have a deep understanding of counter-guerrilla actions, which became the Foreign Internal Defense (FID) mission. The 5th Special Forces Group mixed the UW and FID missions, often leading Vietnamese units such as Montagnards and lowland Civilian Irregular Defense Groups. The deep raid on Son Tay, attempting to recover U.S. prisoners of war, had a ground element completely made up of Special Forces soldiers.
Sources: en.wikipedia.org
=== Content === Drug-free hemp juice contains all of the ingredients of the hemp plant in their natural form and matrix. The highest content of cannabinoids and proteins can be found in the hemp plant prior to seed maturation when the hemp plant is still green. The main ingredients of hemp juice besides the presence omega-n-fatty acids are more than 100 cannabinoids, which are recognized by special receptors in the human body (endocannabinoid system and signal transduction). Hemp is the only botanical source of cannabinoids. Hemp juice contains many easily digestible proteins, in particular all of the eight essential amino acids important for humans. Furthermore, the juice contains a variety of minerals, vitamins and many polyphenols.
1998 A record for the duration of life among males. The Danish-American Christian Mortensen lived 115 years and 252 days. 1998 Scientists managed to extend, in a laboratory environment, the life of normal human cells beyond the Hayflick limit using telomerase. 1999 Establishment of the Buck Institute for Research on Aging – the first institute originally established primarily to study intervention into the aging process. 1999 Sierra Sciences, a biotechnology company focused on aging research with the goal of curing human aging, was founded by William H. Andrews.
== Chemistry == 1S-LSD belongs to the lysergamide class of compounds, which are characterized by the ergoline structure derived from lysergic acid. The compound is closely related to LSD and 1P-LSD but differs by the addition of a trimethylsilyl group on the propionyl chain. The nitrogen atom in the polycyclic indole group of the ergoline structure is a common site for chemical modifications, as it is highly reactive and accessible for various reactions. These modifications often include alkylations, acylations, Mannich reactions, and Michael additions. Such alterations are frequently explored in the synthesis of new analogues to modify pharmacological properties or evade legal controls. The addition of the trimethylsilyl group in 1S-LSD represents a strategic modification designed to keep the substance outside the coverage of Germany's New Psychoactive Substances Act (NpSG). Despite these changes, 1S-LSD likely retains a pharmacological profile similar to that of LSD, acting primarily as a serotonergic hallucinogen.
Sources: en.wikipedia.org
The breeder reactor as its name implies creates larger quantities of 239Pu or 233U (the fissile isotopes) than it consumes. The Clean And Environmentally Safe Advanced Reactor (CAESAR), a nuclear reactor concept that would use steam as a moderator to control delayed neutrons, will potentially be able to use 238U as fuel once the reactor is started with Low-enriched uranium (LEU) fuel. This design is still in the early stages of development.
== Conjugates == Attaching other hormones such as estrogen, thyroid hormone (T3), and dexamethasone to GLP-1 or glucagon restrict the activity of the attached hormone to cells that express GLP-1 or glucagon. GLP-1 and amylin receptor agonist conjugates have also been tested in preclinical trials.
=== Specificity === The specific activities of sv-LAAOs with various L-amino acids have been explored. Many studies show that a number of sv-LAAOs exhibit a preference for hydrophobic L-amino acids as substrates. For example, results have indicated that most sv-LAAOs demonstrate relatively high specificities toward hydrophobic amino acids such as L-Met, L-Leu, and L-Ile in addition to aromatic amino acids such as L-Phe and L-Trp.
Analyzing proteins proves to be more difficult than analyzing nucleic acid sequences. While there are only 4 nucleotides that make up DNA, there are at least 20 different amino acids that can make up a protein. Additionally, there is currently no known high throughput technology to make copies of a single protein. Numerous methods are available to study proteins, sets of proteins, or the whole proteome. In fact, proteins are often studied indirectly, e.g. using computational methods and analyses of genomes. Only a few examples are given below.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.